TY - JOUR
T1 - Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients
AU - Müller-Quernheim, J.
AU - Gaede, K. I.
AU - Fireman, Elizabeth
AU - Zissel, G.
PY - 2006/6
Y1 - 2006/6
N2 - An increase in chronic beryllium disease (CBD) has been suggested due to higher industrial us of beryllium alloys. Since occupational CBD is a perfect phenocopy of sarcoidosis, it might be misdiagnosed as sarcoidosis. In the current it was hypothesised that CBD exists in cohorts of sarcoidosis patients. In a prospective case study, sarcoidosis patients were evaluated for potential beryllium exposure. In those patients in whom beryllium exposure was confirmed and beryllium hypersensitivity demonstrated, the diagnosis of sarcoidosis was rejected and corrected to CBD. In 84 patients seen for re-evaluation or making a diagnosis of sarcoidosis, beryllium exposure was recognised and a diagnosis of CBD was made in 34 out of 84 patients. The time lag between clinical diagnosis of sarcoidosis and the final diagnosis of CBD ranged 0-18 yrs (median 3 yrs) and the mean (range) age at time of diagnosis of CBD was 43.9(25-80) yrs. Beryllium-contaminated workplaces causing disease encompassed a wide spectrum of industries and technical trades in which beryllium-exposure is generally not perceived as a health hazard. In conclusion, chronic beryllium disease still belongs to the spectrum of differential diagnoses of granulomatous disorders.
AB - An increase in chronic beryllium disease (CBD) has been suggested due to higher industrial us of beryllium alloys. Since occupational CBD is a perfect phenocopy of sarcoidosis, it might be misdiagnosed as sarcoidosis. In the current it was hypothesised that CBD exists in cohorts of sarcoidosis patients. In a prospective case study, sarcoidosis patients were evaluated for potential beryllium exposure. In those patients in whom beryllium exposure was confirmed and beryllium hypersensitivity demonstrated, the diagnosis of sarcoidosis was rejected and corrected to CBD. In 84 patients seen for re-evaluation or making a diagnosis of sarcoidosis, beryllium exposure was recognised and a diagnosis of CBD was made in 34 out of 84 patients. The time lag between clinical diagnosis of sarcoidosis and the final diagnosis of CBD ranged 0-18 yrs (median 3 yrs) and the mean (range) age at time of diagnosis of CBD was 43.9(25-80) yrs. Beryllium-contaminated workplaces causing disease encompassed a wide spectrum of industries and technical trades in which beryllium-exposure is generally not perceived as a health hazard. In conclusion, chronic beryllium disease still belongs to the spectrum of differential diagnoses of granulomatous disorders.
KW - Chronic beryllium disease
KW - Diagnosis
KW - Lymphocyte proliferation test
KW - Sarcoidosis
UR - http://www.scopus.com/inward/record.url?scp=33750697248&partnerID=8YFLogxK
U2 - 10.1183/09031936.06.00112205
DO - 10.1183/09031936.06.00112205
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 16540500
AN - SCOPUS:33750697248
SN - 0903-1936
VL - 27
SP - 1190
EP - 1195
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 6
ER -